TY - JOUR
T1 - Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
AU - Ferrajoli, Alessandra
AU - Lee, Bang Ning
AU - Schlette, Ellen J.
AU - O'Brien, Susan
AU - Gao, Hui
AU - Wen, Sijin
AU - Wierda, William G.
AU - Estrov, Zeev
AU - Faderl, Stefan H
AU - Cohen, Evan N.
AU - Li, Changping
AU - Reuben, James M
AU - Keating, Michael J.
PY - 2008/6/1
Y1 - 2008/6/1
N2 - This study investigated the activity of lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Lenalidomide was given at 10 mg daily with dose escalation up to 25 mg daily. Three patients (7%) achieved a complete response (CR), one a nodular partial remission, and 10 patients a partial remission (PR), for an overall response (OR) rate of 32%. Treatment with lenalidomide was associated with an OR rate of 31% in patients with 11q or 17p deletion, of 24% in patients with unmutated VH, and of 25% in patients with fludarabine-refractory disease. The most common toxicity was myelosuppression, and the median daily dose of lenalidomide tolerated was 10 mg. Plasma levels of angiogenic factors, inflammatory cytokines, and cytokine receptors were measured at baseline, day 7, and day 28. There was a dramatic increase in median interleukin (IL)-6, IL-10, IL-2, and tumor necrosis factor receptor-1 levels on day 7, whereas no changes were observed in median vascular endothelial growth factor levels (20 patients studied). According to our experience, lenalidomide given as a continuous treatment has antitumor activity in heavily pretreated patients with CLL. This trial is registered at http://www.clinicaltrials.gov as no. NCT00267059.
AB - This study investigated the activity of lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Lenalidomide was given at 10 mg daily with dose escalation up to 25 mg daily. Three patients (7%) achieved a complete response (CR), one a nodular partial remission, and 10 patients a partial remission (PR), for an overall response (OR) rate of 32%. Treatment with lenalidomide was associated with an OR rate of 31% in patients with 11q or 17p deletion, of 24% in patients with unmutated VH, and of 25% in patients with fludarabine-refractory disease. The most common toxicity was myelosuppression, and the median daily dose of lenalidomide tolerated was 10 mg. Plasma levels of angiogenic factors, inflammatory cytokines, and cytokine receptors were measured at baseline, day 7, and day 28. There was a dramatic increase in median interleukin (IL)-6, IL-10, IL-2, and tumor necrosis factor receptor-1 levels on day 7, whereas no changes were observed in median vascular endothelial growth factor levels (20 patients studied). According to our experience, lenalidomide given as a continuous treatment has antitumor activity in heavily pretreated patients with CLL. This trial is registered at http://www.clinicaltrials.gov as no. NCT00267059.
UR - http://www.scopus.com/inward/record.url?scp=45949100928&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=45949100928&partnerID=8YFLogxK
U2 - 10.1182/blood-2007-12-130120
DO - 10.1182/blood-2007-12-130120
M3 - Article
C2 - 18334676
AN - SCOPUS:45949100928
SN - 0006-4971
VL - 111
SP - 5291
EP - 5297
JO - Blood
JF - Blood
IS - 11
ER -